1
|
Villeneuve C, Humeau A, Monchaud C, Labriffe M, Rerolle JP, Couzi L, Westeel PF, Etienne I, Kamar N, Büchler M, Thierry A, Marquet P. Better Rejection-Free Survival at Three Years in Kidney Transplant Recipients With Model-Informed Precision Dosing of Mycophenolate Mofetil. Clin Pharmacol Ther 2024. [PMID: 38372185 DOI: 10.1002/cpt.3206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Accepted: 01/25/2024] [Indexed: 02/20/2024]
Abstract
The clinical impact of individual dose adjustment of mycophenolate mofetil is still debated, due to conflicting results from randomized clinical trials. This retrospective study aimed to compare 3-year rejection-free survival and adverse effects between adult kidney transplant recipients (KTRs) with or without mycophenolate mofetil model-informed precision dosing (MIPD). MIPD is defined here as mycophenolic acid area under the curve (AUC0-12h ) estimation using a limited sampling strategy, pharmacokinetic models and Bayesian estimators; dose recommendation to reach AUC0-12h = 45 mg.h/L; using a widely used online expert system. The study, nested in two multicenter prospective cohort studies, focused on patients who received a mycophenolate drug and were followed up for 1-3 years. Mycophenolate mofetil MIPD was prescribed as per local practice, on a regular basis, when deemed necessary, or not at all. The MIPD group included 341 KTRs and the control group 392. At 3 years, rejection-free survival was respectively 91.2% and 80.6% (P < 0.001) and the cumulative incidence of rejection 5.08% vs. 12.7% per patient × year (hazard ratio = 0.49 (0.34, 0.71), P < 0.001), corresponding to a 2.5-fold reduction. Significant association with rejection-free survival was confirmed in patients at low or high risk of rejection (P = 0.017 and 0.013) and in patients on tacrolimus, but not on cyclosporine (P < 0.001 and 0.205). The mycophenolate mofetil MIPD group had significantly more adverse effects, but most occurred before the first AUC0-12h , suggesting some may be the reason why MIPD was ordered.
Collapse
Affiliation(s)
- Claire Villeneuve
- Department of Pharmacology, Toxicology and Pharmacovigilance, Centre Hospitalier Universitaire de Limoges, Limoges, France
- Pharmacology & Transplantation, Institut National de la Santé et de la Recherche Médicale U1248, Université de Limoges, Limoges, France
- Fédération Hospitalo-Universitaire SUrvival oPtimization in ORgan Transplantation (FHU SUPORT), Limoges, France
| | - Antoine Humeau
- Pharmacology & Transplantation, Institut National de la Santé et de la Recherche Médicale U1248, Université de Limoges, Limoges, France
- Fédération Hospitalo-Universitaire SUrvival oPtimization in ORgan Transplantation (FHU SUPORT), Limoges, France
| | - Caroline Monchaud
- Department of Pharmacology, Toxicology and Pharmacovigilance, Centre Hospitalier Universitaire de Limoges, Limoges, France
- Pharmacology & Transplantation, Institut National de la Santé et de la Recherche Médicale U1248, Université de Limoges, Limoges, France
- Fédération Hospitalo-Universitaire SUrvival oPtimization in ORgan Transplantation (FHU SUPORT), Limoges, France
| | - Marc Labriffe
- Department of Pharmacology, Toxicology and Pharmacovigilance, Centre Hospitalier Universitaire de Limoges, Limoges, France
- Pharmacology & Transplantation, Institut National de la Santé et de la Recherche Médicale U1248, Université de Limoges, Limoges, France
- Fédération Hospitalo-Universitaire SUrvival oPtimization in ORgan Transplantation (FHU SUPORT), Limoges, France
| | - Jean-Phillipe Rerolle
- Pharmacology & Transplantation, Institut National de la Santé et de la Recherche Médicale U1248, Université de Limoges, Limoges, France
- Fédération Hospitalo-Universitaire SUrvival oPtimization in ORgan Transplantation (FHU SUPORT), Limoges, France
- Department of Nephrology, Dialysis and Transplantation, Centre Hospitalier Universitaire de Limoges, Limoges, France
- Department of Nephrology, Transplantation, Dialysis, Centre Hospitalier Universitaire Pellegrin, Bordeaux, France
| | - Lionel Couzi
- Centre National de la Recherche Scientifique, UMR 5164 Immuno ConcEpT, Bordeaux University, Bordeaux, France
| | - Pierre-François Westeel
- Department of Nephrology and Kidney Transplantation, University Hospital of Amiens, Amiens, France
| | - Isabelle Etienne
- Service de Néphrologie, Rouen University Hospital, Rouen, France
| | - Nassim Kamar
- Department of Nephrology and Organ Transplantation, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- Université Paul Sabatier, Toulouse, France
- Institut National de la Santé et de la Recherche Médicale, U1043, IFR-BMT, Centre Hospitalier Universitaire Purpan, Toulouse, France
| | - Mathias Büchler
- Fédération Hospitalo-Universitaire SUrvival oPtimization in ORgan Transplantation (FHU SUPORT), Limoges, France
- Department of Nephrology and Kidney Transplantation, University Hospital of Tours, Tours, France
- François Rabelais University, Tours, France
| | - Antoine Thierry
- Fédération Hospitalo-Universitaire SUrvival oPtimization in ORgan Transplantation (FHU SUPORT), Limoges, France
- Department of Nephrology, Dialysis and Transplantation, Centre Hospitalier Universitaire de Poitiers, Tours, France
| | - Pierre Marquet
- Department of Pharmacology, Toxicology and Pharmacovigilance, Centre Hospitalier Universitaire de Limoges, Limoges, France
- Pharmacology & Transplantation, Institut National de la Santé et de la Recherche Médicale U1248, Université de Limoges, Limoges, France
- Fédération Hospitalo-Universitaire SUrvival oPtimization in ORgan Transplantation (FHU SUPORT), Limoges, France
| |
Collapse
|
2
|
Monchaud C, Villeneuve C, Belaiche S, Charbit M, Colosio C, Houssel P, Meurette A, Nubret K, Tissot A, Albouy M, Esposito L. French Recommendations for a National Competency Framework of Therapeutic Patient Education in Solid Organ Transplantation. Transplantation 2023; 107:549-553. [PMID: 36808841 DOI: 10.1097/tp.0000000000004354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Affiliation(s)
- Caroline Monchaud
- Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Limoges, Limoges, France
- INSERM UMR-1248 Pharmacologie & Transplantation, Limoges, France
| | - Claire Villeneuve
- INSERM UMR-1248 Pharmacologie & Transplantation, Limoges, France
- Unité de Vigilance des Essais Cliniques, CHU Limoges, Limoges, France
| | - Stéphanie Belaiche
- Institut de Pharmacie, CHU Lille, Lille, France
- Service d'Hépatologie-Transplantation, CHU Lille, Lille, France
| | - Marina Charbit
- Service de Néphrologie Pédiatrique, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | | | | | - Aurélie Meurette
- Service de Néphrologie et Immunologie Clinique, CHU Nantes, Nantes, France
| | - Karine Nubret
- Service de Traitement de l'insuffisance Cardiaque, CHU Bordeaux, Bordeaux, France
| | | | - Marion Albouy
- Ecology and Biology of Interaction Lab, CNRS UMR 7267, University of Poitiers, Poitiers, France
- Clinical Centre for Investigation, INSERM 1402, CHU Poitiers, Poitiers, France
- BioSPharm Pole, Public Health department, CHU Poitiers, Poitiers, France
| | - Laure Esposito
- Département de Néphrologie, Dialyse et Transplantation D'organes, CHU Toulouse, Toulouse, France
| |
Collapse
|
3
|
Villeneuve C, Rerolle JP, Couzi L, Westeel PF, Etienne I, Esposito L, Kamar N, Büchler M, Thierry A, Marquet P, Monchaud C. Therapeutic education as a tool to improve patient-reported and clinical outcomes after renal transplantation: results of the EPHEGREN multicenter retrospective cohort study. Transpl Int 2021; 34:2341-2352. [PMID: 34585793 DOI: 10.1111/tri.14127] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Revised: 08/11/2021] [Accepted: 09/06/2021] [Indexed: 12/30/2022]
Abstract
Patients are not always aware of the inconveniences associated with renal transplantation, which they compare with a « rebirth », and from which they expect complete recovery. Therapeutic education is proposed to prepare patients for their life after transplantation. This study evaluated the impact of pretransplant therapeutic education on patient-reported outcomes and rejection-free survival over the first year. We collected data from 383 renal transplant patients followed-up in seven centers. Patients who benefited from therapeutic education before transplantation (N = 182) were compared with patients who did not (N = 139) for quality-of-life, adherence and adverse events using the Pearson's chi-square test, one-way ANOVA or t-test. The association between therapeutic education and time to acute rejection was investigated using Cox models. The patients who benefited from therapeutic education reported adverse events less frequently (e.g., tremor: 9% vs. 32.4%, P = 0.01) and better quality-of-life (MCS-QOL: 50.7 ± 8.1 vs. 47.7 ± 9.5, P = 0.02; PCS-QOL: 49.1 ± 7.1 vs. 46.0 ± 9.2, P = 0.013). No difference was found on adherence. Rejection-free survival was slightly better in the therapeutic education group (HR = 0.44, 95% CI = [0.19-1.01]). This multicenter retrospective cohort study suggests that integrating therapeutic education to care pathways entails clinical benefit, in terms of quality-of-life, self-reported adverse events and rejection-free survival. Randomized clinical trials are necessary to confirm this.
Collapse
Affiliation(s)
- Claire Villeneuve
- Department of Pharmacology, Toxicology and Centre of Pharmacovigilance, CHU Limoges, Limoges, France.,UMR-1248, INSERM, Limoges, France.,FHU SUPORT, Limoges, France
| | - Jean-Phillipe Rerolle
- UMR-1248, INSERM, Limoges, France.,FHU SUPORT, Limoges, France.,Department of Nephrology, Dialysis and Transplantation, CHU Limoges, Limoges, France
| | - Lionel Couzi
- Department of Nephrology, Transplantation, Dialysis, Centre Hospitalier Universitaire (CHU) Pellegrin, Bordeaux, France.,CNRS-UMR 5164 Immuno ConcEpT, Bordeaux University, Bordeaux, France
| | - Pierre-Francois Westeel
- Department of Nephrology and Kidney Transplantation, University Hospital of Amiens, Amiens, France
| | - Isabelle Etienne
- Service de Nephrologie, Rouen University Hospital, Rouen, France
| | - Laure Esposito
- Department of Nephrology and Organ Transplantation, CHU Toulouse, Toulouse, France
| | - Nassim Kamar
- Department of Nephrology and Organ Transplantation, CHU Toulouse, Toulouse, France.,Université Paul Sabatier, Toulouse, France.,INSERM U1043, IFR-BMT, CHU Purpan, Toulouse, France
| | - Mathias Büchler
- FHU SUPORT, Limoges, France.,University Hospital of Tours, Tours, France.,François Rabelais University, Tours, France
| | - Antoine Thierry
- FHU SUPORT, Limoges, France.,Department of Nephrology, Dialysis and Transplantation, CHU Poitiers, Poitiers, France
| | - Pierre Marquet
- Department of Pharmacology, Toxicology and Centre of Pharmacovigilance, CHU Limoges, Limoges, France.,UMR-1248, INSERM, Limoges, France.,FHU SUPORT, Limoges, France.,Faculty of Medicine, University of Limoges, Limoges, France
| | - Caroline Monchaud
- Department of Pharmacology, Toxicology and Centre of Pharmacovigilance, CHU Limoges, Limoges, France.,UMR-1248, INSERM, Limoges, France.,FHU SUPORT, Limoges, France
| |
Collapse
|
4
|
Petitpain N, Olivier P, Crépin S, Leone E, Ouk T, Villeneuve C, Muller C, Ruault S, Jamet A, Franceschi MP, Duranton S, Gavard M. Overview of clinical trials vigilance units in French institutional sponsors - A study from the REVISE working group. Therapie 2021; 76:743-750. [PMID: 33993991 DOI: 10.1016/j.therap.2021.04.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Revised: 03/29/2021] [Accepted: 04/09/2021] [Indexed: 10/21/2022]
Abstract
PURPOSE To follow the European Directive 2001/20/EC, institutional sponsors created or reinforced their vigilance units. Since 2007, the working group "REflexion sur la VIgilance et la Sécurité des Essais" (REVISE) rallies French institutional vigilance units (IVUs) to share their experience. The group decided to elaborate a collective work to provide a real-life descriptive picture of French IVUs activities and resources over the 2011-2016 period. METHOD A questionnaire was sent to the 60 IVUs of the group. It included questions on staff and activities, such as the number of received and analyzed serious adverse events (SAEs). All results and proposals were discussed and consensus was achieved in general meeting. RESULTS/CONCLUSION The results highlight the commitment of IVU staffs at many steps of CTs, but also the frailty of some units, leading to 6 proposals intended to institutional sponsors and competent authorities for ensuring (1) IVU visibility to all actors; (2) sustainable IVU staff; (3) IVU resources adapted to sponsor's ambitions; (4) valorization of IVUs in publications; (5) recognition of IVU's value in clinical research quality; (6) involvement of IVUs in regulatory changes and their procedures of implementation.
Collapse
Affiliation(s)
- Nadine Petitpain
- Service de pharmacologie clinique, toxicologie, unité de vigilance des essais cliniques, Centre régional de pharmacovigilance, CHRU de Nancy, bâtiment de biologie et de biopathologie, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France.
| | - Pascale Olivier
- Service de pharmacologie médicale et clinique, centre de pharmacovigilance, de pharmacoépidémiologie et d'informations sur le médicament INSERM UMR 1027, CIC 1436, faculté de médecine, centre hospitalier universitaire, 31059 Toulouse, France
| | - Sabrina Crépin
- Service de pharmacologie, toxicologie et pharmacovigilance, unité de vigilance des essais cliniques, CHU de Limoges, 87000 Limoges, France
| | - Emanuela Leone
- Unité de vigilance des essais cliniques, Hôpital Foch, 92151 Suresnes, France
| | - Thavarak Ouk
- Cellule vigilance, direction de la recherche et de l'innovation, CHU de Lille, 59045 Lille, France
| | - Claire Villeneuve
- Service de pharmacologie, toxicologie et pharmacovigilance, unité de vigilance des essais cliniques, CHU de Limoges, 87000 Limoges, France
| | - Charlotte Muller
- Vigilance des essais cliniques, hôpitaux universitaires de Strasbourg, 67091 Strasbourg, France
| | - Sophie Ruault
- Maison de la recherche clinique, CHU de Rouen, 76031 Rouen, France
| | - Aurélie Jamet
- Vigilance des essais cliniques, CHU d'Angers, 49933 Angers, France
| | - Marie-Paule Franceschi
- Direction de la recherche, des partenariats hospitalo-universitaires et internationaux, CHU de Nîmes, Université de Montpellier, 30029 Nîmes, France
| | - Sophie Duranton
- Direction de la recherche, unité de vigilance des essais cliniques, CHU de Poitiers, 86021 Poitiers cedex, France
| | - Marylaure Gavard
- Cellule de vigilance des essais cliniques-délégation à la recherche clinique et à l'innovation - CHU de Grenoble-Alpes, 38043 Grenoble, France
| |
Collapse
|
5
|
Roux B, Sirois C, Niquille A, Spinewine A, Ouellet N, Pétein C, Sibille FX, Csajka C, Reeve E, Villeneuve C, Laroche ML. Cross-cultural adaptation and psychometric validation of the revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire in French. Res Social Adm Pharm 2020; 17:1453-1462. [PMID: 33317980 DOI: 10.1016/j.sapharm.2020.11.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Revised: 11/04/2020] [Accepted: 11/05/2020] [Indexed: 12/31/2022]
Abstract
BACKGROUND The revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire allows capture of the beliefs and attitudes of older adults and caregivers towards deprescribing. OBJECTIVES To translate and validate the rPATD questionnaire into French. METHODS The French rPATD was translated using forward-backward translation. Psychometric properties were evaluated in both older adults ≥65 years living in the community or in institutions and who were taking at least one chronic medication and in caregivers of older adults with similar characteristics. Participants were recruited in four French-speaking countries (Belgium, Canada, France and Switzerland). Face and content validity were assessed during the translation process. Construct validity (exploratory factor analysis (EFA)) and internal consistency (Cronbach's alpha) were investigated in questionnaires without missing data. Test-retest reliability was evaluated using intra-class correlation coefficient (ICC) in a sample of participants. RESULTS In total, 320 questionnaires from older adults and 215 questionnaires from caregivers were included to evaluate construct validity and internal consistency. EFA extracted four factors in the older adults' and caregivers' versions of the questionnaire consistent with the English rPATD. The extracted factors related to the perceived burden of medication taking, the beliefs in appropriateness of medications, concerns about stopping medications and the level of involvement in making decisions and of knowledge of medications. Internal consistency was satisfactory for three factors for both versions (Cronbach's alpha >0.70), with lower internal consistency in the concerns about stopping factor. Test-retest reliability was overall good for all factors in the caregivers' version (ICC > 0.75) while for the older adults' version, moderate (ICC range: 0.75-0.50) to good ICC values were found. CONCLUSIONS The French rPATD presents globally good psychometric properties and can be used to explore attitudes towards deprescribing in French-speaking older adults and caregivers.
Collapse
Affiliation(s)
- Barbara Roux
- Centre of Pharmacovigilance and Pharmacoepidemiology, Department of Pharmacology-Toxicology and Centre of Pharmacovigilance, University Hospital of Limoges, Limoges, France; INSERM UMR 1248, Faculty of Medicine, University of Limoges, Limoges, France.
| | - Caroline Sirois
- Faculty of Medicine, Department of Social and Administrative Pharmacy, Laval University, Quebec, Canada; Centre of Excellence on Aging of Quebec, Quebec, Canada; Centre de Recherche sur les soins et les services de premières lignes de l'Université Laval, Quebec, Canada
| | - Anne Niquille
- Community Pharmacy, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland; Community Pharmacy, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Switzerland; Center for Research and Innovation in Clinical Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Anne Spinewine
- UCLouvain, Louvain Drug Research Institute, Clinical Pharmacy Research Group, Brussels, Belgium; CHU UCL Namur, Pharmacy Department, Yvoir, Belgium
| | - Nicole Ouellet
- Department of Nursing, University of Quebec at Rimouski, Rimouski, Canada
| | - Catherine Pétein
- UCLouvain, Louvain Drug Research Institute, Clinical Pharmacy Research Group, Brussels, Belgium
| | - François-Xavier Sibille
- UCLouvain, Institute of Health and Society, Brussels, Belgium; CHU UCL Namur, Geriatric Medicine, Yvoir, Belgium
| | - Chantal Csajka
- Center for Research and Innovation in Clinical Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, University Hospital and University of Lausanne, Lausanne, Switzerland; School of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
| | - Emily Reeve
- Quality Use of Medicines and Pharmacy Research Centre, UniSA: Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia; Geriatric Medicine Research, Faculty of Medicine, Dalhousie University and Nova Scotia Health Authority, Halifax, NS, Canada; College of Pharmacy, Dalhousie University, Halifax, NS, Canada
| | - Claire Villeneuve
- Centre of Pharmacovigilance and Pharmacoepidemiology, Department of Pharmacology-Toxicology and Centre of Pharmacovigilance, University Hospital of Limoges, Limoges, France; INSERM UMR 1248, Faculty of Medicine, University of Limoges, Limoges, France
| | - Marie-Laure Laroche
- Centre of Pharmacovigilance and Pharmacoepidemiology, Department of Pharmacology-Toxicology and Centre of Pharmacovigilance, University Hospital of Limoges, Limoges, France; INSERM UMR 1248, Faculty of Medicine, University of Limoges, Limoges, France
| |
Collapse
|
6
|
Villeneuve C, Rousseau A, Rerolle JP, Couzi L, Kamar N, Essig M, Etienne I, Westeel PF, Büchler M, Esposito L, Thierry A, Marquet P, Monchaud C. Adherence profiles in kidney transplant patients: Causes and consequences. Patient Educ Couns 2020; 103:189-198. [PMID: 31447197 DOI: 10.1016/j.pec.2019.08.002] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/14/2018] [Revised: 07/30/2019] [Accepted: 08/01/2019] [Indexed: 06/10/2023]
Abstract
OBJECTIVE Adherence is a dynamic phenomenon and a critical determinant of transplant patients outcome. The objective of this longitudinal study was to explore adherence in kidney transplant patients followed-up for up to three years after transplantation. METHODS Adherence was repeatedly estimated using the Morisky-Green-Levine 4-Item Medication Adherence Scale, in two successive cohorts of 345 (EPIGREN) and 367 (EPHEGREN) kidney transplant recipients. Mixed effect modeling with latent processes and latent classes was used to describe adherence time-profiles. RESULTS Two latent classes were identified. The adherent class represented 85% of the patients. Patients of the poorer-adherence class displayed a lower adherence at one month (p<10-3), which worsened over time. Good adherence was associated with age >50 years, fewer depression episodes (5% vs. 13%, p = 0.001) and a better mental health component of quality of life (MCS-SF36 47 ± 11 vs. 41 ± 13, p = 0.015). Survival without acute rejection episodes was longer in the adherent class (p = 0.004). CONCLUSIONS The risk of poor adherence in renal transplant patients can be detected as early as one month post-transplantation, using appropriate and easy tools adapted to routine monitoring. PRACTICE IMPLICATIONS An early focus on vulnerable patients should allow putting into place actions in order to reduce the risk of poor outcome related to poor adherence.
Collapse
Affiliation(s)
- Claire Villeneuve
- CHU Limoges, Department of Pharmacology, Toxicology and Centre of Pharmacovigilance, F-87000 Limoges, France; INSERM, UMR-1248, F-87000 Limoges, France.
| | - Annick Rousseau
- INSERM, UMR-1248, F-87000 Limoges, France; FHU SUPORT, Limoges, F-87000, France; Univ Limoges, Faculty of Pharmacy, Department of Biophysics, F-87000 Limoges, France
| | - Jean-Phillipe Rerolle
- INSERM, UMR-1248, F-87000 Limoges, France; FHU SUPORT, Limoges, F-87000, France; Department of Nephrology, Dialysis and Transplantation, F-87000, Limoges, France
| | - Lionel Couzi
- Department of Nephrology, Transplantation, Dialysis, Centre Hospitalier Universitaire (CHU) Pellegrin, Bordeaux, France; CNRS-UMR 5164 Immuno ConcEpT, Bordeaux University, Bordeaux, France
| | - Nassim Kamar
- Department of Nephrology and Organ Transplantation, CHU Toulouse, Toulouse, France; Université Paul Sabatier, Toulouse, France; INSERM U1043, IFR-BMT, CHU Purpan, Toulouse, France
| | - Marie Essig
- INSERM, UMR-1248, F-87000 Limoges, France; FHU SUPORT, Limoges, F-87000, France; Department of Nephrology, Dialysis and Transplantation, F-87000, Limoges, France; Univ Limoges, Faculty of Medicine, F-87000 Limoges, France
| | - Isabelle Etienne
- Service de Nephrologie, Rouen University Hospital, Rouen, France
| | - Pierre-Francois Westeel
- Department of Nephrology and Kidney Transplantation, University Hospital of Amiens, Amiens, France
| | - Mathias Büchler
- FHU SUPORT, Limoges, F-87000, France; Department of Nephrology and Kidney Transplantation, University Hospital of Tours, Tours, France; François Rabelais University, EA 4245 Tours, France
| | - Laure Esposito
- Department of Nephrology and Organ Transplantation, CHU Toulouse, Toulouse, France
| | - Antoine Thierry
- FHU SUPORT, Limoges, F-87000, France; CHU Poitiers, Department of Nephrology, Dialysis and Transplantation, F-86000 Poitiers, France
| | - Pierre Marquet
- CHU Limoges, Department of Pharmacology, Toxicology and Centre of Pharmacovigilance, F-87000 Limoges, France; INSERM, UMR-1248, F-87000 Limoges, France; FHU SUPORT, Limoges, F-87000, France; Univ Limoges, Faculty of Medicine, F-87000 Limoges, France
| | - Caroline Monchaud
- CHU Limoges, Department of Pharmacology, Toxicology and Centre of Pharmacovigilance, F-87000 Limoges, France; INSERM, UMR-1248, F-87000 Limoges, France; FHU SUPORT, Limoges, F-87000, France
| |
Collapse
|
7
|
Villeneuve C, Dahdah N. THE SHIFTING ANATOMY OF THE PATENT DUCTS ARTERIOSUS - A RETROSPECTIVE STUDY FROM A SINGLE TERTIARY HEART CENTER. Can J Cardiol 2018. [DOI: 10.1016/j.cjca.2018.07.337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
8
|
Bourbonnais D, Villeneuve C, Bellavance C, Lalumière Boucher M, Goyette M. A new methodology to re-educate muscle synergies observed during gait. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.1016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
9
|
Villeneuve C, Woillard JB, Knoop C, Essig M, Etienne I, Epailly E, Pison C, Debette-Gratien M, Marquet P, Monchaud C. Evaluation of Experiences with Immunosuppressive Drugs in Transplantation: Validation of the MESI Scale in French. Pharmaceut Med 2017. [DOI: 10.1007/s40290-017-0207-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Beauger D, Fruit D, Villeneuve C, Laroche ML, Jouve E, Rousseau A, Boyer L, Gentile S. Validation of the psychometrics properties of a French quality of life questionnaire among a cohort of renal transplant recipients less than one year. Qual Life Res 2016; 25:2347-59. [PMID: 27016945 DOI: 10.1007/s11136-016-1271-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/12/2016] [Indexed: 11/28/2022]
Abstract
BACKGROUND Renal transplantation is considered as the treatment of choice for patients with end-stage renal disease. Health-related quality of life (HRQoL) of renal transplant recipients (RTR) is very important to assess, especially during the first year after transplantation. To provide new evidence about the suitability of HRQoL measures in RTR during the first post-transplant year, we explored the internal structure, reliability and external validity of a French specific HRQoL instrument, the Renal Transplant Quality of life Questionnaire Second Version (RTQ V2). METHODS The data were issued from the French multicenter cohort of renal transplant patients followed during 4 years (EPIGREN). The HRQoL of RTR was assessed five times (at 1, 3, 6, 9 and 12 months after transplantation) with the RTQ V2, a specific instrument consisting of 32 items describing five dimensions. Socio-demographic information, clinical characteristics and HRQoL (i.e., RTQ V2 and SF-36) were collected. For the five times, psychometric properties of the RTQ V2 were compared to those reported from the reference population assessed in the validation study. RESULTS Three hundred and thirty-four patients were enrolled. The proportions of well-projected items, item-internal consistency, item-discriminant validity, floor and ceiling effects, Cronbach's alpha coefficients and item goodness-of-fit statistics were satisfactory for each dimension at the five times of the study. The suitability indices of construct validity were higher than 90 % for each time (minimum-maximum: 90.8-97.4 %). The external validity was less satisfactory, with a suitability indices ranged from 46.7 % at M1 to 66.7 % at M12. However, the discrepancies with the reference population (mainly for the gender) appeared logical considering the scientific literature on HRQoL of RTR during the first post-transplant year and may not compromise the external validity. CONCLUSION These results support the validity and reliability of the RTQ V2 for evaluating HRQoL in RTR during the first post-transplant year, and confirm that the RTQ V2 is a useful tool to assess the HRQoL precociously after transplant.
Collapse
Affiliation(s)
- Davy Beauger
- EA 3279 - Public Health, Chronic Diseases and Quality of Life - Research Unit, Aix-Marseille University, 13005, Marseille, France.
| | - Dorothée Fruit
- Department of Pharmacology, Toxicology and Centre of Pharmacovigilance, CHU Limoges, Limoges, France.,INSERM, UMR-S850, Limoges, France.,Faculty of Medicine, Laboratory of Clinical Pharmacology, Univ Limoges, Limoges, France
| | - Claire Villeneuve
- Department of Pharmacology, Toxicology and Centre of Pharmacovigilance, CHU Limoges, Limoges, France.,INSERM, UMR-S850, Limoges, France
| | - Marie-Laure Laroche
- Department of Pharmacology, Toxicology and Centre of Pharmacovigilance, CHU Limoges, Limoges, France.,Faculty of Medicine, Laboratory of Clinical Pharmacology, Univ Limoges, Limoges, France
| | - Elisabeth Jouve
- Medical Evaluation and Public Health Department, Assistance Publique - Hôpitaux de Marseille, Marseille, France
| | - Annick Rousseau
- INSERM, UMR-S850, Limoges, France.,Faculty of Pharmacy, Department of Biophysics, Univ Limoges, Limoges, France
| | - Laurent Boyer
- EA 3279 - Public Health, Chronic Diseases and Quality of Life - Research Unit, Aix-Marseille University, 13005, Marseille, France
| | - Stéphanie Gentile
- EA 3279 - Public Health, Chronic Diseases and Quality of Life - Research Unit, Aix-Marseille University, 13005, Marseille, France
| |
Collapse
|
11
|
Pouché L, Koitka M, Stojanova J, Woillard JB, Monchaud C, Villeneuve C, Essig M, Abraham J, Le Meur Y, Rerolle JP, Kamar N, Rostaing L, Merville P, Gandia P, Bouchet S, Petersen BS, Marquet P, Picard N. A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation. Pharmacogenomics 2016; 17:375-91. [PMID: 26894651 DOI: 10.2217/pgs.15.181] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
AIM To investigate the potential influence of variants in genes involved in the calcineurin pathway on the efficacy and toxicity of calcineurin inhibitors in renal transplantation. MATERIALS & METHODS Twenty-three polymorphisms in thirteen genes were tested in 381 renal transplant recipients receiving ciclosporin (n = 221) or tacrolimus (n = 160) and mycophenolate mofetil. Data were collected prospectively over the first year post-transplantation. RESULTS Multivariate survival analyses revealed no genetic associations with biopsy proven acute graft rejection and serious infections. Donor-recipient Cytomegalovirus mismatch was the only variable associated with serious infection. CONCLUSION This large exploratory study casts doubts on the potential interest of genetic biomarkers related to CNI pharmacodynamics but associations with other phenotypes in transplantation deserve further studies.
Collapse
Affiliation(s)
- Lucie Pouché
- Inserm, UMR 850, 2 Avenue Martin-Luther King, F-87042 Limoges, France.,Univ. Limoges, Faculty of Medicine & Pharmacy, 2 rue du Dr Marcland, F-87025 Limoges, France.,CHU Limoges, Department of Pharmacology, Toxicology & Pharmacovigilance, 2 Avenue Martin-Luther King, F-87042 Limoges, France
| | - Matthias Koitka
- Inserm, UMR 850, 2 Avenue Martin-Luther King, F-87042 Limoges, France.,Univ. Limoges, Faculty of Medicine & Pharmacy, 2 rue du Dr Marcland, F-87025 Limoges, France
| | - Jana Stojanova
- Inserm, UMR 850, 2 Avenue Martin-Luther King, F-87042 Limoges, France.,Univ. Limoges, Faculty of Medicine & Pharmacy, 2 rue du Dr Marcland, F-87025 Limoges, France.,Laboratory of Chemical Carcinogenesis & Pharmacogenetics, University of Chile, Santiago, Chile
| | - Jean-Baptiste Woillard
- Inserm, UMR 850, 2 Avenue Martin-Luther King, F-87042 Limoges, France.,Univ. Limoges, Faculty of Medicine & Pharmacy, 2 rue du Dr Marcland, F-87025 Limoges, France.,CHU Limoges, Department of Pharmacology, Toxicology & Pharmacovigilance, 2 Avenue Martin-Luther King, F-87042 Limoges, France
| | - Caroline Monchaud
- Inserm, UMR 850, 2 Avenue Martin-Luther King, F-87042 Limoges, France.,CHU Limoges, Department of Pharmacology, Toxicology & Pharmacovigilance, 2 Avenue Martin-Luther King, F-87042 Limoges, France
| | - Claire Villeneuve
- Inserm, UMR 850, 2 Avenue Martin-Luther King, F-87042 Limoges, France.,Univ. Limoges, Faculty of Medicine & Pharmacy, 2 rue du Dr Marcland, F-87025 Limoges, France.,CHU Limoges, Department of Pharmacology, Toxicology & Pharmacovigilance, 2 Avenue Martin-Luther King, F-87042 Limoges, France
| | - Marie Essig
- Inserm, UMR 850, 2 Avenue Martin-Luther King, F-87042 Limoges, France.,Univ. Limoges, Faculty of Medicine & Pharmacy, 2 rue du Dr Marcland, F-87025 Limoges, France.,CHU Limoges, Department of Nephrology, Dialysis & Transplantation, 2 Avenue Martin-Luther King, F-87042 Limoges, France
| | - Julie Abraham
- CHU Limoges, Department of Clinical Hematology, 2 Avenue Martin-Luther King, F-87042 Limoges, France
| | - Yannick Le Meur
- CHU Brest, Hôpital Cavale Blanche, Department of Nephrology, F-29609 Brest, France
| | - Jean-Phillippe Rerolle
- CHU Limoges, Department of Nephrology, Dialysis & Transplantation, 2 Avenue Martin-Luther King, F-87042 Limoges, France
| | - Nassim Kamar
- CHU Toulouse Rangueil, Department of Nephrology & Organ Transplantation, F-31000 Toulouse, France.,INSERM, U1043, Structure Fédérative de Recherche Bio-Médicale de Toulouse (SFR-BMT), Centre Hospitalier Universitaire (CHU) Purpan, Toulouse, France.,Université Paul Sabatier, 118 route de Narbonne, F-31062 Toulouse, France
| | - Lionel Rostaing
- CHU Toulouse Rangueil, Department of Nephrology & Organ Transplantation, F-31000 Toulouse, France.,INSERM, U1043, Structure Fédérative de Recherche Bio-Médicale de Toulouse (SFR-BMT), Centre Hospitalier Universitaire (CHU) Purpan, Toulouse, France.,Université Paul Sabatier, 118 route de Narbonne, F-31062 Toulouse, France
| | - Pierre Merville
- CHU Bordeaux, Department of Nephrology, Transplantation, Dialysis, F-33000 Bordeaux, France
| | - Peggy Gandia
- CHU Toulouse, Laboratory of Pharmacokinetics & Clinical Toxicology, F-31000 Toulouse, France
| | - Stephane Bouchet
- CHU Bordeaux, Department of Clinical Pharmacology & Toxicology, F-33000 Bordeaux, France
| | - Britt-Sabina Petersen
- Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, Germany
| | - Pierre Marquet
- Inserm, UMR 850, 2 Avenue Martin-Luther King, F-87042 Limoges, France.,Univ. Limoges, Faculty of Medicine & Pharmacy, 2 rue du Dr Marcland, F-87025 Limoges, France.,CHU Limoges, Department of Pharmacology, Toxicology & Pharmacovigilance, 2 Avenue Martin-Luther King, F-87042 Limoges, France
| | - Nicolas Picard
- Inserm, UMR 850, 2 Avenue Martin-Luther King, F-87042 Limoges, France.,Univ. Limoges, Faculty of Medicine & Pharmacy, 2 rue du Dr Marcland, F-87025 Limoges, France.,CHU Limoges, Department of Pharmacology, Toxicology & Pharmacovigilance, 2 Avenue Martin-Luther King, F-87042 Limoges, France
| |
Collapse
|
12
|
Crépin S, Villeneuve C, Merle L. Quality of serious adverse events reporting to academic sponsors of clinical trials: far from optimal. Pharmacoepidemiol Drug Saf 2016; 25:719-24. [DOI: 10.1002/pds.3982] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2015] [Revised: 12/15/2015] [Accepted: 01/17/2016] [Indexed: 11/09/2022]
Affiliation(s)
- Sabrina Crépin
- Service de Pharmacologie-Toxicologie et Pharmacovigilance; CHU de Limoges; Limoges France
| | - Claire Villeneuve
- Service de Pharmacologie-Toxicologie et Pharmacovigilance; CHU de Limoges; Limoges France
| | - Louis Merle
- Service de Pharmacologie-Toxicologie et Pharmacovigilance; CHU de Limoges; Limoges France
| |
Collapse
|
13
|
Crepin S, Godet B, Carrier P, Villeneuve C, Merle L, Laroche ML. Probable drug-induced liver injury associated with aliskiren: Case report and review of adverse event reports from pharmacovigilance databases. Am J Health Syst Pharm 2014; 71:643-7. [DOI: 10.2146/ajhp130149] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Affiliation(s)
- Sabrina Crepin
- Department of Pharmacology–Toxicology, Pharmacovigilance
| | | | - Paul Carrier
- Department of Hepatogastroenterology, Limoges University Hospital, Limoges, France
| | - Claire Villeneuve
- Department of Pharmacology–Toxicology, Pharmacovigilance, Limoges University Hospital
| | - Louis Merle
- Department of Pharmacology–Toxicology, Pharmacovigilance, Limoges University Hospital
| | - Marie-Laure Laroche
- Department of Pharmacology–Toxicology, Pharmacovigilance, Limoges University Hospital
| |
Collapse
|
14
|
Mouls M, Paravisini L, Crépin S, Villeneuve C, Boussaroque A, Laroche ML. Bilan de pharmacovigilance des inhibiteurs de l’acétylcholinesterase en France. Rev Epidemiol Sante Publique 2012. [DOI: 10.1016/j.respe.2012.06.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
15
|
Villeneuve C, Caudrillier A, Ordener C, Pizzinat N, Parini A, Mialet-Perez J. Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol 2009; 297:H821-8. [DOI: 10.1152/ajpheart.00345.2009] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
There is substantial evidence supporting a hypertrophic action of serotonin [5-hydroxytryptamine (5-HT)] in cardiomyocytes. However, little is known about the mechanisms involved. We previously demonstrated that 5-HT-induced hypertrophy depends, in part, on the generation of reactive oxygen species by monoamine oxidase-A (MAO-A) (see Ref. 3 ). Cardiomyocytes express 5-HT2 receptors, which may also participate in hypertrophy. Here, we analyzed the respective contribution of 5-HT2 receptors and MAO-A in H9C2 cardiomyoblast hypertrophy. 5-HT induced a dose-dependent increase in [3H]leucine incorporation and stimulation of two markers of cardiac hypertrophy, ANF-luc and αSK-actin-luc reporter genes. Experiments using 1 μM 5-HT showed that hypertrophic response occurred independently from MAO-A. Using pharmacological inhibitors (M100907 and ketanserin), we identified a novel mechanism of action involving 5-HT2A receptors and requiring Ca2+/calcineurin/nuclear factor of activated T-cell activation. The activation of this hypertrophic pathway was fully prevented by 5-HT2A inhibitors and was unaffected by MAO inhibition. When 10 μM 5-HT was used, an additional hypertrophic response, prevented by the MAO inhibitors pargyline and RO 41-1049, was observed. Unlike the 5-HT2A-receptor-mediated H9C2 cell hypertrophy, MAO-A-dependent hypertrophic response required activation of extracellular-regulated kinases. In conclusion, our results show the existence of a dose-dependent shift of activation of distinct intracellular pathways involved in 5-HT-mediated hypertrophy of cardiac cells.
Collapse
|
16
|
Villeneuve C, Guilbeau-Frugier C, Lairez O, Ordener C, Delisle MB, Parini A, Mialet-Perez J. C016 Contribution du stress oxydant genere par la MAO-A au cours de la degradation de la serotonine dans le remodelage cardiaque associe au vieillissement. Arch Cardiovasc Dis 2009. [DOI: 10.1016/s1875-2136(09)72203-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
17
|
Knott V, McIntosh J, Millar A, Fisher D, Villeneuve C, Ilivitsky V, Horn E. Nicotine and smoker status moderate brain electric and mood activation induced by ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist. Pharmacol Biochem Behav 2006; 85:228-42. [PMID: 17023037 DOI: 10.1016/j.pbb.2006.08.005] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2006] [Revised: 08/01/2006] [Accepted: 08/09/2006] [Indexed: 11/18/2022]
Abstract
As the increased smoking prevalence in schizophrenics may be interpreted as an adaptive response to an underlying biological defect, investigations into nicotine's actions within N-methyl-d-aspartate (NMDA) antagonist drug models of schizophrenia may improve our understanding of the role of glutamatergic neurotransmission in initiating and maintaining nicotine dependence in this disorder. In this double-blind, placebo-controlled, randomized study, the electroencephalographic (EEG) and subjective response to a sub-psychotomimetic intravenous dose of the NMDA antagonist ketamine was examined in 20 regular smokers and 20 non-smokers pretreated with placebo or nicotine gum. Although nicotine increased EEG arousal, ketamine produced electrocerebral signs of brain activation (decreased slow wave power) and sedation (decreased fast wave power and frequency), which were not affected by nicotine pretreatment and were evident only in non-smokers. Ketamine increased a number of self-report indices of subjective arousal, some of which were attenuated and potentiated by nicotine in smokers and non-smokers, respectively. These findings suggest that long-term (evidenced by smoker vs. non-smoker comparisons) and short-term (acute) nicotine exposure may alter NMDA receptor-mediated arousal and mood systems in a way that promotes nicotine dependence in smokers, and addresses neurobiological deficiencies in smokers with schizophrenia.
Collapse
Affiliation(s)
- V Knott
- Clinical Neuroelectrophysiology and Cognitive Research Laboratory, University of Ottawa Institute of Mental Health Research, Royal Ottawa Hospital, Ottawa, ON, Canada.
| | | | | | | | | | | | | |
Collapse
|
18
|
Parent J, Villeneuve C, Fortier MA. Evaluation of the contribution of cyclooxygenase 1 and cyclooxygenase 2 to the production of PGE2 and PGF2 alpha in epithelial cells from bovine endometrium. Reproduction 2004; 126:539-47. [PMID: 14525536 DOI: 10.1530/rep.0.1260539] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
In ruminants, the production of prostaglandins by the endometrium is critical for recognition of pregnancy. In the absence of an embryonic signal, luteolytic pulses of PGF(2 alpha) are released by the uterus. In contrast, the presence of a viable conceptus reduces the production of PGF(2 alpha) relative to PGE(2) and prevents luteolysis through the release of trophoblastic interferon (IFN-tau). Initially, it was thought that epithelial and stromal endometrial cells were specialized in the production of a single type of prostaglandin. However, purified cell populations of both types of cell can produce PGF(2 alpha) and PGE(2); therefore, selective production of PGF(2 alpha) and PGE(2) must be regulated within each type of cell. Two distinct prostaglandin synthases, cyclooxygenase 1 and cyclooxygenase 2, are involved in prostaglandin production and each may catalyse the production of a different prostaglandin. This possibility was investigated in cultured epithelial cells from bovine endometrium. Cells were treated with oxytocin or arachidonic acid, and expression of cyclooxygenase 1 and cyclooxygenase 2 proteins was monitored over time and correlated with prostaglandin accumulation. Cells were also treated with increasing doses of inhibitors of cyclooxygenase 1 or cyclooxygenase 2 (non-steroidal anti-inflammatory drugs; NSAIDs) with or without arachidonic acid or oxytocin: flurbiprofen (0-50 micromol l(-1)) was used as a non-selective inhibitor; valeryl salicylate (0-500 micromol l(-1)) was used as a cyclooxygenase 1 inhibitor and NS-398 (0-1 micromol l(-1)) was used as a cyclooxygenase 2 inhibitor. After stimulation with arachidonic acid or oxytocin, prostaglandin production and expression of cyclooxygenase 2 protein were increased. All inhibitors were able to block basal and stimulated prostaglandin production. These results indicate that in endometrium most, if not all, prostaglandin production is probably processed through cyclooxygenase 2.
Collapse
Affiliation(s)
- J Parent
- Unité de Recherche en Ontogénie et Reproduction, Centre Hospitalier Universitaire de Québec, Centre de Recherche en Biologie de la Reproduction, Ste-Foy, QC, Canada G1V 4G2
| | | | | |
Collapse
|
19
|
Abstract
There has been much debate on the value and risks of long-term enteral feeding in patients with advanced dementia. A retrospective study was carried out on 47 patients with a primary diagnosis of dementia who died over a two-year period. All were inpatients in a nursing home or skilled nursing facility. Marked weight loss and dysphagia occurring in a specific pattern were found to be associated with death from pneumonia. These clinical features probably imply failure of basic homeostatic mechanisms. Patients showing this clinical pattern may be less likely to show benefits from long-term enteral feeding.
Collapse
Affiliation(s)
- J Chouinard
- Sisters of Charity at Ottawa Hospital, Ontario, Canada
| | | | | |
Collapse
|
20
|
Abstract
OBJECTIVE To examine several subjective components of adolescents' behaviour concerning mental illness prevention. METHOD Adolescents' knowledge, their attitudes and subjective norms, as well as their thoughts about how they would concretely handle a psychological problem were measured. A self-administered questionnaire was completed by 438 male and female adolescents in grades 8 and 11. RESULTS Gender and age differences were revealed: girls and older adolescents were more attuned to prevention. Further, the influence on young people of peers and parents was also apparent. CONCLUSION Adolescents perceive prevention concerning mental health as important.
Collapse
Affiliation(s)
- C Villeneuve
- Department of Psychiatry, Université de Montréal, Quebec
| | | | | | | |
Collapse
|
21
|
Slater GW, Desruisseaux C, Villeneuve C, Guo HL, Drouin G. Trapping gel electrophoresis of end-labeled DNA: an analytical model for mobility and diffusion. Electrophoresis 1995; 16:704-12. [PMID: 7588548 DOI: 10.1002/elps.11501601114] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
As shown by Ulanovsky, Drouin and Gilbert (Nature 1990, 343, 190-192), the gel electrophoretic migration of DNA is severely reduced by steric trapping when streptavidin is attached to one end of the polyelectrolyte. We present a model that allows us to calculate both the mobility and the diffusion coefficient, hence the resolution factor of the resulting separation. We compare our results to those of Défontaines and Viovy (Electrophoresis 1993, 14, 8-17) and we show that the averages over the molecular conformations must be done carefully. We also show that trapping increases diffusion substantially and that this makes constant-field trapping electrophoresis incapable of increasing the number of bases read per sequencing run. Finally, we conclude that severe trapping may lead to highly anomalous transport behavior where one cannot define a velocity or a diffusion constant.
Collapse
Affiliation(s)
- G W Slater
- Department of Physics, University of Ottawa, Ontario, Canada
| | | | | | | | | |
Collapse
|
22
|
Abstract
The psychological impact of ultrasound examination on expectant parents is assessed through direct observation, interviews and the administration of a questionnaire to a large group of parents. The examination was a positive and reassuring experience for most parents. Among a wide array of variables that could account for the effects of the exam, the results were the most important. Women viewing their first ultrasound, specially primiparae were more moved. The results did not confirm that there is a traumatic effect when viewing precedes quickening. Contrary to previous reports, fathers were as emotionally involved as the mothers. The presence of the father seemed also to have a beneficial effect on the mother. One-half of parents wanted to know the sex of the fetus before birth. These findings are discussed, along with implications for problems arising from introduction of new technologies during pregnancy.
Collapse
|
23
|
Villeneuve C. [Integration of the psychoanalytical and systemic approaches in the diagnostic process]. Neuropsychiatr Enfance Adolesc 1984; 32:459-64. [PMID: 6504277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
24
|
Villeneuve C. [Evaluation of the family.]. Sante Ment Que 1983; 8:122-7. [PMID: 17093793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
The author discusses the clinical family evaluation. He discusses its advantages, and difficulties, as well its dangers, and presents a model of family evaluation. Although developped with a view to a child psychiatry practice, this model could also be applied to other mental health intervention contexts. The model in question is based on family interactions and considers the developmental level of the children. In the course of the evaluation, the family is invited to accomplish some activities in which the children can participate. Clinical cases serve to illustrate the model. The family evaluation should facilitate a better understanding of the child's psychological problems.
Collapse
|
25
|
|
26
|
Dupras G, Villeneuve C. Camera aperture to optimize data collection in nuclear medicine. Eur J Nucl Med 1979; 4:397-8. [PMID: 520351 DOI: 10.1007/bf00263312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Collection of data with a large field of view camera can cause problems when a small organ like the heart is to be imaged, especially when high activity is used. A simple, inexpensive mask is described that solves most of these problems.
Collapse
|
27
|
Dupras G, Villeneuve C. [Radioisotope ventriculography and the computation of the ejection fraction]. Union Med Can 1978; 107:63-6. [PMID: 625841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
28
|
Jus A, Villeneuve A, Gautier J, Jus K, Villeneuve C, Pires P, Villeneuve R. Deanol, lithium and placebo in the treatment of tardive dyskinesia. A double-blind crossover study. Neuropsychobiology 1978; 4:140-9. [PMID: 340975 DOI: 10.1159/000117629] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
A double-blind crossover study on the effects of deanol and lithium carbonate was conducted on a sample of 29 chronic schizophrenic patients with tardive dyskinesia. In addition to his usual treatment with different neuroleptics, each patient received during an 8-week period either deanol, lithium carbonate or placebo. A 4-week wash-out period was inserted between each of the 8-week periods of experimental treatment of the tardive dyskinesia. The administration of either deanol, lithium carbonate or placebo added to the neuroleptic treatment did not produce a statistically significant improvement of tardive dyskinesia in our patient population as a whole. Favorable and unfavorable responses are discussed.
Collapse
|
29
|
Villeneuve C, Maugile D, Derome T. [Observing children in peer groups during clinical evaluation]. Can Psychiatr Assoc J 1974; 19:387-91. [PMID: 4426021 DOI: 10.1177/070674377401900410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
This paper describes the observation of the child in a peer group as part of his evaluation in a clinical setting. The observation is divided into three parts and done in a play atmosphere. First, the children meet and do craft activities. Afterwards they are left alone in this room and observed from another room; then they are free to do whatever they like, using material selected in advance. Finally the activities are structured by two participant observers. The observation is particularly useful for evaluating the social functioning of the child and, more especially, his relationships with his peers, which are interpreted only by the traditional method of evaluation. The observation usually corroborates the findings of other sources and also often brings new insights. A better understanding of various aspects of the psychosocial development and of some components of the ego is often revealed. The findings in this paper are illustrated with extracts from case histories.
Collapse
|
30
|
|
31
|
Kourounakis P, Szabo S, Villeneuve C, Gagnon M. Effect of pharmacologic or surgical conditioning upon intoxication with arsenicals. Eur J Toxicol Hyg Environ 1973; 6:232-6. [PMID: 4784496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
32
|
Sigal JJ, Chagoya L, Villeneuve C, Mayerovitch J. Later psychological consequences of near-fatal illness (nephrosis) in early childhood: some preliminary findings. Laval Med 1971; 42:103-108. [PMID: 5551740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|
33
|
Villeneuve C, Ananth JV, Ban TA, Lehmann HE. CI-601, a butyrophenone derivative, in the treatment of chronically withdrawn schizophrenic patients. Curr Ther Res Clin Exp 1970; 12:223-9. [PMID: 4985943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|